PROSTATE CANCER (ADENOCARCINOMA)
Clinical trials for PROSTATE CANCER (ADENOCARCINOMA) explained in plain language.
Never miss a new study
Get alerted when new PROSTATE CANCER (ADENOCARCINOMA) trials appear
Sign up with your email to follow new studies for PROSTATE CANCER (ADENOCARCINOMA), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Promising combo for Hard-to-Treat prostate cancer enters first human tests
Disease control Not yet recruitingThis early-phase study tests a combination of chemotherapy (docetaxel) and a targeted radioactive drug (177Lu-PSMA) in 18 men with advanced prostate cancer that has stopped responding to hormone therapy. The main goal is to find the safest dose of the chemotherapy when given with…
Matched conditions: PROSTATE CANCER (ADENOCARCINOMA)
Phase: PHASE1 • Sponsor: Instituto do Cancer do Estado de São Paulo • Aim: Disease control
Last updated May 26, 2026 03:18 UTC
-
New combo therapy aims to stop prostate cancer recurrence in High-Risk patients
Disease control Not yet recruitingThis study tests whether adding the drug rezvilutamide to standard hormone therapy can lower the risk of prostate cancer returning in patients who have had their prostate removed. About 33 high-risk patients will take rezvilutamide daily for up to 2 years along with hormone shots…
Matched conditions: PROSTATE CANCER (ADENOCARCINOMA)
Phase: NA • Sponsor: Fujian Medical University Union Hospital • Aim: Disease control
Last updated May 26, 2026 03:16 UTC
-
Could surgery after hormone therapy curb advanced prostate cancer?
Disease control Not yet recruitingThis study looks at men with advanced prostate cancer that has spread to other parts of the body. After 6 months of hormone therapy, those whose scans show no active cancer may be randomly assigned to either continue hormone therapy alone or also have their prostate removed. The …
Matched conditions: PROSTATE CANCER (ADENOCARCINOMA)
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated May 26, 2026 03:16 UTC
-
New combo therapy for advanced prostate cancer enters early testing
Disease control Not yet recruitingThis early-phase study tests a new drug called LC-K76 combined with standard hormone therapy in 40 men with metastatic hormone-sensitive prostate cancer. The main goal is to check safety and side effects, while also looking at how well it controls the cancer, such as lowering PSA…
Matched conditions: PROSTATE CANCER (ADENOCARCINOMA)
Phase: EARLY_PHASE1 • Sponsor: Shanghai Changzheng Hospital • Aim: Disease control
Last updated May 26, 2026 03:13 UTC
-
Vitamin d fix may boost immunity in black men with prostate cancer
Disease control Not yet recruitingThis study tests whether fixing vitamin D deficiency in Black and West African men with prostate cancer can strengthen their immune system and improve quality of life. About 200 men with low vitamin D will take daily supplements for 8 weeks and be followed for up to 3 years. Rese…
Matched conditions: PROSTATE CANCER (ADENOCARCINOMA)
Phase: PHASE3 • Sponsor: University of Ilorin Teaching Hospital • Aim: Disease control
Last updated May 26, 2026 03:03 UTC
-
New hope for advanced prostate cancer: drug combo aims to delay progression
Disease control Not yet recruitingThis study tests whether adding mevrometostat to enzalutamide can slow cancer growth in people with metastatic castration-resistant prostate cancer (mCRPC) who have already taken similar drugs. About 60 adults with confirmed prostate cancer that has spread to bone or soft tissue …
Matched conditions: PROSTATE CANCER (ADENOCARCINOMA)
Phase: PHASE2 • Sponsor: Prostate Cancer Clinical Trials Consortium • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
New program aims to protect cancer Patients' hearts during treatment
Disease control Not yet recruitingThis study tests a program called Primary Care Connect (PC2) for cancer survivors who also have heart-related conditions like high blood pressure, diabetes, or high cholesterol. The goal is to see if the program helps them stay connected to their primary care doctor and better ma…
Matched conditions: PROSTATE CANCER (ADENOCARCINOMA)
Phase: NA • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated May 12, 2026 13:42 UTC
-
Smarter radiation: fewer sessions, fewer side effects for prostate cancer
Disease control Not yet recruitingThis study tests a personalized radiation approach for men whose prostate cancer has returned after surgery. Using PSMA PET scans, doctors will give higher radiation doses to areas with cancer and lower doses to healthy tissue. The goal is to reduce side effects while keeping tre…
Matched conditions: PROSTATE CANCER (ADENOCARCINOMA)
Phase: PHASE2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated May 04, 2026 16:18 UTC
-
Glow-in-the-Dark dye could spot prostate cancer cells during biopsy
Diagnosis Not yet recruitingThis early-stage trial tests a fluorescent dye called AS1986NS that may help doctors see prostate cancer cells during a biopsy. Ten men with suspected prostate cancer will receive a tiny dose of the dye before their standard biopsy. The main goal is to check if the dye is safe an…
Matched conditions: PROSTATE CANCER (ADENOCARCINOMA)
Phase: PHASE1, PHASE2 • Sponsor: Antelope Surgical Solutions, Inc • Aim: Diagnosis
Last updated May 06, 2026 16:03 UTC
-
Prostate cancer Treatment's hidden cost: study tracks sexual side effects
Symptom relief Not yet recruitingThis study follows 130 men with unfavorable intermediate-risk prostate cancer to see how a combination of targeted radiation (SBRT) and 6 months of hormone therapy (ADT) impacts their sexual function. Researchers will measure erectile function before treatment and again at 24 mon…
Matched conditions: PROSTATE CANCER (ADENOCARCINOMA)
Sponsor: CancerCare Manitoba • Aim: Symptom relief
Last updated May 26, 2026 03:27 UTC